Candel Therapeutics IncNASDAQ:CADL
- LAST PRICE5.6500
- TODAY'S CHANGE (%)-0.5000 (-8.1301%)
- Bid / Lots5.7000/ 17
- Ask / Lots5.9000/ 1
- Open / Previous Close6.1700 / 6.1500
- Day Range
- 52 Week Range
- Volume339,477
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CADL |
|---|---|---|
| 09:32 ET | 792 | 6.15 |
| 09:34 ET | 7866 | 6.155 |
| 09:38 ET | 100 | 6.15 |
| 09:39 ET | 2000 | 6.0601 |
| 09:41 ET | 275 | 6.15 |
| 09:43 ET | 1497 | 6.15 |
| 09:45 ET | 900 | 6.2 |
| 09:50 ET | 270 | 6.175 |
| 09:52 ET | 1200 | 6.15 |
| 09:54 ET | 200 | 6.12 |
| 09:56 ET | 450 | 6.15 |
| 09:57 ET | 100 | 6.12 |
| 10:03 ET | 3673 | 6.175 |
| 10:06 ET | 1562 | 6.16 |
| 10:08 ET | 300 | 6.15 |
| 10:10 ET | 100 | 6.15 |
| 10:12 ET | 10715 | 6.07 |
| 10:14 ET | 400 | 6.11 |
| 10:17 ET | 200 | 6.12 |
| 10:21 ET | 100 | 6.15 |
| 10:28 ET | 630 | 6.15 |
| 10:32 ET | 600 | 6.15 |
| 10:35 ET | 390 | 6.15 |
| 10:39 ET | 214 | 6.13 |
| 10:42 ET | 100 | 6.13 |
| 10:48 ET | 220 | 6.13 |
| 10:50 ET | 825 | 6.13 |
| 10:51 ET | 1130 | 6.132 |
| 10:53 ET | 2210 | 6.1026 |
| 10:55 ET | 4604 | 6.0656 |
| 10:57 ET | 100 | 6.07 |
| 11:00 ET | 900 | 6.09 |
| 11:02 ET | 1250 | 6.09 |
| 11:06 ET | 500 | 6.07 |
| 11:08 ET | 800 | 6.07 |
| 11:09 ET | 2400 | 6.0764 |
| 11:11 ET | 609 | 6.12 |
| 11:18 ET | 283 | 6.1 |
| 11:24 ET | 100 | 6.12 |
| 11:26 ET | 200 | 6.095 |
| 11:27 ET | 100 | 6.115 |
| 11:29 ET | 200 | 6.12 |
| 11:31 ET | 100 | 6.124 |
| 11:36 ET | 100 | 6.14 |
| 11:40 ET | 164 | 6.1001 |
| 11:42 ET | 100 | 6.14 |
| 11:45 ET | 898 | 6.14 |
| 11:49 ET | 300 | 6.15 |
| 11:51 ET | 100 | 6.155 |
| 11:56 ET | 1200 | 6.1589 |
| 11:58 ET | 200 | 6.16 |
| 12:00 ET | 3641 | 6.15 |
| 12:05 ET | 100 | 6.125 |
| 12:07 ET | 300 | 6.11 |
| 12:12 ET | 200 | 6.15 |
| 12:14 ET | 100 | 6.15 |
| 12:16 ET | 1996 | 6.11 |
| 12:18 ET | 100 | 6.15 |
| 12:21 ET | 100 | 6.135 |
| 12:23 ET | 100 | 6.12 |
| 12:30 ET | 200 | 6.12 |
| 12:32 ET | 300 | 6.1 |
| 12:34 ET | 100 | 6.1 |
| 12:38 ET | 200 | 6.11 |
| 12:41 ET | 100 | 6.105 |
| 12:43 ET | 1100 | 6.09 |
| 12:45 ET | 100 | 6.105 |
| 12:48 ET | 1073 | 6.09 |
| 12:50 ET | 877 | 6.07 |
| 12:52 ET | 200 | 6.085 |
| 12:56 ET | 100 | 6.07 |
| 12:57 ET | 350 | 6.0843 |
| 01:03 ET | 217 | 6.08 |
| 01:08 ET | 261 | 6.05 |
| 01:10 ET | 1301 | 6.03 |
| 01:12 ET | 100 | 6.02 |
| 01:15 ET | 1400 | 6.04 |
| 01:17 ET | 400 | 6.03 |
| 01:19 ET | 933 | 6 |
| 01:24 ET | 100 | 6.025 |
| 01:28 ET | 100 | 6.025 |
| 01:32 ET | 100 | 6.025 |
| 01:39 ET | 2725 | 6 |
| 01:42 ET | 2265 | 5.99 |
| 01:46 ET | 100 | 6 |
| 01:48 ET | 1053 | 5.98 |
| 01:50 ET | 200 | 5.97 |
| 01:51 ET | 2215 | 5.96 |
| 01:53 ET | 400 | 5.97 |
| 01:57 ET | 100 | 5.975 |
| 02:00 ET | 1200 | 5.93 |
| 02:02 ET | 2300 | 5.92 |
| 02:04 ET | 640 | 5.9397 |
| 02:06 ET | 1700 | 5.94 |
| 02:08 ET | 200 | 5.93 |
| 02:11 ET | 100 | 5.93 |
| 02:13 ET | 802 | 5.9364 |
| 02:15 ET | 100 | 5.91 |
| 02:18 ET | 200 | 5.92 |
| 02:20 ET | 1413 | 5.93 |
| 02:22 ET | 1652 | 5.94 |
| 02:24 ET | 586 | 5.935 |
| 02:26 ET | 1314 | 5.925 |
| 02:27 ET | 1100 | 5.93 |
| 02:29 ET | 750 | 5.9299 |
| 02:31 ET | 3728 | 5.9 |
| 02:33 ET | 1686 | 5.91 |
| 02:36 ET | 400 | 5.92 |
| 02:38 ET | 100 | 5.92 |
| 02:40 ET | 300 | 5.9108 |
| 02:42 ET | 300 | 5.91 |
| 02:44 ET | 1706 | 5.92 |
| 02:45 ET | 400 | 5.925 |
| 02:47 ET | 400 | 5.925 |
| 02:49 ET | 429 | 5.915 |
| 02:51 ET | 1294 | 5.915 |
| 02:54 ET | 2801 | 5.915 |
| 02:56 ET | 516 | 5.92 |
| 02:58 ET | 600 | 5.91 |
| 03:00 ET | 491 | 5.91 |
| 03:03 ET | 9706 | 5.9 |
| 03:07 ET | 250 | 5.9099 |
| 03:09 ET | 863 | 5.8801 |
| 03:12 ET | 489 | 5.88 |
| 03:14 ET | 916 | 5.85 |
| 03:16 ET | 1996 | 5.85 |
| 03:18 ET | 2603 | 5.84 |
| 03:20 ET | 870 | 5.86 |
| 03:21 ET | 200 | 5.85 |
| 03:23 ET | 200 | 5.84 |
| 03:25 ET | 200 | 5.84 |
| 03:27 ET | 672 | 5.845 |
| 03:30 ET | 4669 | 5.84 |
| 03:32 ET | 840 | 5.86 |
| 03:34 ET | 1101 | 5.85 |
| 03:36 ET | 1300 | 5.8599 |
| 03:38 ET | 500 | 5.85 |
| 03:39 ET | 4229 | 5.81 |
| 03:41 ET | 12874 | 5.82 |
| 03:43 ET | 2100 | 5.8199 |
| 03:45 ET | 2798 | 5.78 |
| 03:48 ET | 3767 | 5.77 |
| 03:50 ET | 9365 | 5.75 |
| 03:52 ET | 5383 | 5.69 |
| 03:54 ET | 6788 | 5.645 |
| 03:56 ET | 9569 | 5.64 |
| 03:57 ET | 11412 | 5.6 |
| 03:59 ET | 61444 | 5.65 |
Jun 18, 2024
Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference, from 8:00AM ET on Tuesday Jun 18, 2024 by Dow Jones
8:00AM ET on Tuesday Jun 18, 2024 by Dow Jones
Jun 11, 2024
Candel Therapeutics to Join Russell 3000(R) Index, from 8:00AM ET on Tuesday Jun 11, 2024 by Dow Jones
8:00AM ET on Tuesday Jun 11, 2024 by Dow Jones
Jun 3, 2024
May 30, 2024
DJ Candel Therapeutics Gets FDA's Orphan-Drug Status for Glioma Treatment, from 8:30AM ET on Thursday May 30, 2024 by Dow Jones
8:30AM ET on Thursday May 30, 2024 by Dow JonesFDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma, from 8:00AM ET on Thursday May 30, 2024 by Dow Jones
8:00AM ET on Thursday May 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Candel Therapeutics Inc | 183.0M | -4.4x | --- |
Trevi Therapeutics Inc | 185.9M | -7.7x | --- |
Gossamer Bio Inc | 186.9M | -1.0x | --- |
Pyxis Oncology Inc | 187.9M | -2.2x | --- |
Design Therapeutics Inc | 189.8M | -3.2x | --- |
Ventyx Biosciences Inc | 175.5M | -0.7x | --- |
Company Information
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The Company has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is in ongoing clinical trials in non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is in an ongoing investigator-sponsored phase I clinical trial in recurrent high-grade glioma (HGG). Its enLIGHTEN Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors.
Contact Information
- Headquarters
- 117 Kendrick Street,, Suite 450NEEDHAM, MA, United States 02494
- Phone
- 617-916-5445
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Paul Manning
- President, Chief Executive Officer, Director
- Paul Tak
- Interim Chief Financial Officer
- Charles Schoch
- Chief Scientific Officer
- Francesca Barone
- Vice President - Development Leader
- Christopher Matheny
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $183.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 29.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.29 |
Book Value | $0.44 |
P/E Ratio | -4.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
